| Bioactivity | Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke[1]. |
| Name | Ralpancizumab |
| CAS | 1407495-04-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sanz-Cuesta BE, et al. Lipid-Lowering Therapy and Hemorrhagic Stroke Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors. Stroke. 2021 Oct;52(10):3142-3150. |